comparemela.com
  1. Home
  2. Live Updates
  3. Ue Avxl Us0327973006 - Breaking News

Ue Avxl Us0327973006 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ANAVEX®2–73 (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints, Showing Statistically Significant Reduction of Clinical Decline in Global Clinical Study of Patients With Early Alzheimer’s Disease

Anavex Life Sciences Corp. announced positive topline results from its Phase 2b/3 ANAVEX®2-73-AD-004 clinical trial of oral ANAVEX®2-73 for the treatment of mild cognitive impairment due to. | December 2, 2022

San franciscoUnited statesAnavex life sciences corpAnavex life sciencesClinical trialsOdds ratioClinical dementia rating scale sumAnavex life sciences corp stock exchangePress releaseUe avxl us0327973006

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.